



ASX Announcement

2 March 2020

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
Sydney NSW 2000

Lapse of Unlisted Options

Melbourne, Australia, 2 March 2020 – The Board of Directors of Avecho Biotechnology Limited (ASX: AVE), an Australian drug delivery company, advises that the following options have lapsed.

ASX Code	Number of options
AVEAS	3,000,000 <i>Options</i> issued on 23 May 2014, expired on 22 May 2019
AVEAS	33,948,150 <i>2016 Options</i> issued on 6 October 2016, expiring 10 September 2021
AVEAS	15,000,000 <i>2016 Options</i> issued on 5 June 2017, expiring 10 September 2021
AVEAS	1,500,000 <i>2016 Options</i> issued on 5 June 2017, expiring 10 September 2021

The Company's current capital structure therefore constitutes of the following securities:

ASX Code	Total number of securities and description
AVE	1,577,457,420 Fully Paid Ordinary Shares
AVEAS	3,750,000 <i>2017 Options</i> issued on 5 June 2017, expiring 10 September 2021

For enquiries, please contact

Melanie Leydin
Company Secretary
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited (ASX:AVE) develops and commercialises innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM® (Targeted Penetration Matrix). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced patches, gels and injectable products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - avecho.com.au